GlaxoSmithKline News and Research

RSS

Seven NIH research contracts awarded to identify novel adjuvant candidates

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded seven research contracts to discover and characterize new adjuvants, or substances formulated as part of vaccines to enhance their protective ability.

30 Sep 2014

Drug firms shift sales calls from doctors to administrators controlling hospital formularies

Since many hospitals now work to help keep costs down by watching what drugs are used, pharmaceutical representatives must include administrators in their sales pitches. Also in the news, new concerns about the government's plan to open a database next week on drug makers' payments to doctors.

26 Sep 2014

Avalon Ventures, GSK jointly launch two new early-stage life science companies

Avalon Ventures today announced the launch of two new companies formed through its collaboration with GlaxoSmithKline to fund and launch up to 10 early-stage life science companies.

23 Sep 2014

Dyspnoea in COPD patients heralds worse outcomes

Breathlessness is a common finding in patients with chronic obstructive pulmonary disease and signals an increased risk of exacerbations, study findings indicate.

3 Sep 2014

International consortium to accelerate collaborative multi-site trials of potential Ebola vaccine

A candidate Ebola vaccine could be given to healthy volunteers in the UK, The Gambia and Mali as early as September, as part of an series of safety trials of potential vaccines aimed at preventing the disease that has killed more than 1,400 people in the current outbreak in West Africa.

29 Aug 2014

NIH to start initial human testing of investigational Ebola vaccine next week

Initial human testing of an investigational vaccine to prevent Ebola virus disease will begin next week by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

29 Aug 2014

FDA approves GlaxoSmithKline’s Arnuity Ellipta for treatment of asthma

GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older. Arnuity is not indicated for relief of acute bronchospasm.

21 Aug 2014

Tarsa obtains $10 million senior credit facility to support NDA submission for Ostora tablet

Tarsa Therapeutics, Inc. today announced that it has secured a $10 million senior credit facility from Oxford Finance LLC and Square 1 Bank. The company intends to use the proceeds to support its plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration for its Ostora tablet for the treatment of postmenopausal osteoporosis, currently targeted for early 2015.

13 Aug 2014

Study shows sustained immunogenicity, efficacy and safety of GlaxoSmithKline's HPV vaccine

A long-term follow-up study (HPV-023; NCT00518336) shows the sustained efficacy, immunogenicity and safety of GlaxoSmithKline's human papilloma virus (HPV) vaccine Cervarix.

1 Aug 2014

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK today announced that once-weekly Tanzeum (albiglutide), a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in pharmacies throughout the U.S.

29 Jul 2014

Zydelig gets FDA approval for treatment of patients with three types of blood cancers

The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers.

24 Jul 2014

Isis earns $1 million payment from GSK related to advancement of ISIS-TTRRx

Isis Pharmaceuticals, Inc. announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).

16 Jul 2014

Scientists release recommendations for evaluating pharmacological safety of oligonucleotide therapeutics

Novel oligonucleotide-based drugs in development offer promising alternatives for treating a range of diseases.

8 Jul 2014

Study analyzes effects of antidepressant drugs on well-being in children and adolescents

In an article published in the current issue of Psychotherapy and Psychosomatics the effects of antidepressant drugs on well-being in children and adolescents are analyze.

7 Jul 2014

Isis Pharmaceuticals gets $1 million from GSK to discover and develop drugs for HBV

Isis Pharmaceuticals, Inc. announced today that it has earned a $1 million payment from GlaxoSmithKline related to the advancement of its program to develop antisense drugs to treat hepatitis B virus (HBV).

2 Jul 2014

Apitope starts preclinical development of ATX-GD-459 for Graves' disease treatment

Apitope, the drug discovery and development company focused on disease-modifying treatments for patients with autoimmune and allergic diseases, announced today that it has started preclinical development of its novel peptide therapy ATX-GD-459 for the treatment of Graves' disease.

19 Jun 2014

GlaxoSmithKline News and Research

Seven NIH research contracts awarded to identify novel adjuvant candidates

Drug firms shift sales calls from doctors to administrators controlling hospital formularies

Avalon Ventures, GSK jointly launch two new early-stage life science companies

Dyspnoea in COPD patients heralds worse outcomes

International consortium to accelerate collaborative multi-site trials of potential Ebola vaccine

NIH to start initial human testing of investigational Ebola vaccine next week

FDA approves GlaxoSmithKline’s Arnuity Ellipta for treatment of asthma

Tarsa obtains $10 million senior credit facility to support NDA submission for Ostora tablet

Study shows sustained immunogenicity, efficacy and safety of GlaxoSmithKline's HPV vaccine

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

Zydelig gets FDA approval for treatment of patients with three types of blood cancers

Isis earns $1 million payment from GSK related to advancement of ISIS-TTRRx

Scientists release recommendations for evaluating pharmacological safety of oligonucleotide therapeutics

Study analyzes effects of antidepressant drugs on well-being in children and adolescents

Isis Pharmaceuticals gets $1 million from GSK to discover and develop drugs for HBV

Apitope starts preclinical development of ATX-GD-459 for Graves' disease treatment

Generic drug delays cost U.S. payers millions

First Edition: June 18, 2014

New study show direct link between depression and medication nonadherence

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News